Samsung Biologics Bets $280M on First U.S. Plant in Maryland
Samsung Biologics is making a major move into the U.S. market. The Korean CDMO is spending $280 million to acquire and upgrade a former GSK plant in Maryland, aiming to boost drug manufacturing capacity.